ReviewmBio2025
Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery.
Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Review of the Therapeutic Challenges and Novel Treatment Options in Mitigating Invasive Mycosis Associated withJournal of fungi (Basel, Switzerland) · 2026Review
- In Vitro Antifungal and Wound-Healing Potential ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fungal biofilms are complex microbial structures associated with persistent and progressive infections, such as cryptococcal meningitis, invasive aspergillosis, and invasive candidiasis, leading to thousands of deaths annually. The prevalence of fungal biofilm formation during infections, with its heightened resistance to antifungal drugs, highlights the urgency for the discovery and development of new antifungals with antibiofilm activity. Current advances in mass spectrometry-based proteomics and computational platforms provide a powerful toolkit to accelerate drug discovery from target identification to optimization of a lead molecule. In this review, we highlight fungal biofilms of four critical priority fungal pathogens (as deemed by the World Health Organization) and define important technological considerations for proteomics and computational methodologies. Additionally, we explore recent proteomics and computational applications within fungal biofilms for the identification and elucidation of biological mechanisms underscoring biofilm formation as well as the discovery of novel putative antibiofilm targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.